Cell Line Development
AmProtein offers comprehensive services for stable, high-yielding mammalian cell lines used in antibody and recombinant protein therapeutic development and manufacturing. Most importantly AmProtein provides all of the relevant intellectual property rights for the developed cell lines and its further commercialization process (refer to intellectual property page).
Proteins with different sizes and properties successfully expressed using the pMH vector series
|
Project Name |
Stable production speed (pg/cell/day) |
Molecular Size |
Posttranslational modification |
Other Features |
|
Erbitux (anti-EGFR) |
80 |
Large |
|
Antibody |
|
Fc-IL-1ra |
120 |
Medium |
|
Fc -Fusion Protein |
|
Campath (anti-CD52) |
118 |
Large |
|
Antibody |
|
EPO |
72 |
Small |
Heavily glycosylated |
|
|
EPO-HyperG |
300 |
Small |
Heavily glycosylated |
Fusion molecule |
|
Enbrel (TNFR2-Fc) |
116 |
Large |
|
|
|
HBsAg |
90 |
Small |
|
Membrane lipid vesicle |
Key Advantages:
- AmProtein covers all intellectual property rights for its cell lines and manufacturing process and can transfer them accordingly to facilitate the customer's commercialization rights (freedom to operate).
- No upfront payment until we reach the customer's requirements
- Multiple extremely high-yielding production clones for freedom of choice
- Initial commercial cell line delivered within 4 weeks
LICENSING
This vector series can be licensed out commercially for commercial research and commercial product development.
AmProtein values academic research that continues to benefit mankind and therefore provides affordable academic licenses.
For more information about AmProtein Cell Line Development & Process Development Services, partnerships, and other opportunities, please contact us.
 |
 |
 |